Author: admin

“Amyotrophic Lateral Sclerosis Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Amyotrophic Lateral Sclerosis Market.

The Amyotrophic Lateral Sclerosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Amyotrophic Lateral Sclerosis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Amyotrophic Lateral Sclerosis treatment therapies with a considerable amount of success over the years.

• Amyotrophic Lateral Sclerosis companies working in the treatment market are Aeterna Zentaris, GeNeuro SA, ProJenX, QurAlis Corporation, Wave Life Sciences, Revalesio Corporation, AI THERAPEUTICS, CYTOKINETICS, Ionis Pharmaceuticals, and others, are developing therapies for the Amyotrophic Lateral Sclerosis treatment

• Emerging Amyotrophic Lateral Sclerosis therapies in the different phases of clinical trials are- AEZS-130, GNK 301, Prosetin, QRL 201, WVE-004, RNS60, AIT-101, Reldesemtiv, ION363, and others are expected to have a significant impact on the Amyotrophic Lateral Sclerosis market in the coming years.

• In January 2025, The US Food and Drug Administration (FDA) has authorized Zydus Lifesciences to initiate a randomized Phase IIb clinical trial of Usnoflast, its oral NLRP3 inflammasome inhibitor, for the treatment of amyotrophic lateral sclerosis (ALS). This multi-center, double-blind, placebo-controlled study will evaluate the drug’s safety, pharmacodynamics, efficacy, and pharmacokinetics in adult ALS patients.

• In January 2025, The US Food and Drug Administration (FDA) has removed the clinical hold on Amylyx Pharmaceuticals’ Phase I trial of AMX0114 for amyotrophic lateral sclerosis (ALS). With the hold lifted, Amylyx can now initiate screening, enrollment, and dosing at US sites for the Phase I LUMINA study (NCT06665165). This multi-center, multiple ascending dose trial will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of AMX0114 in 48 ALS patients. Participants will be randomized in a 3:1 ratio to receive either AMX0114 or a placebo via intrathecal injection every four weeks, for up to four doses.

• In December 2024, Ractigen Therapeutics has administered the first dose in its randomized Phase I clinical trial of RAG-17, a small interfering RNA (siRNA) therapy designed to treat amyotrophic lateral sclerosis (ALS) linked to mutations in the superoxide dismutase 1 (SOD1) gene. The initial dosing took place at the Second Affiliated Hospital of Zhejiang University School of Medicine. This placebo-controlled, double-blind study aims to evaluate the therapy’s pharmacokinetics, preliminary efficacy, pharmacodynamics, and overall safety and tolerability in individuals with SOD1-related ALS.

• In September 2024, QurAlis Corporation, a clinical-stage biotechnology company focused on developing precision medicines with the potential to transform the treatment of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases, announced today that it has completed dosing for the first participant cohort in its Phase 1 multiple-ascending dose (MAD) clinical trial of QRL-101 (QRL-101-03; NCT06532396). QRL-101 is a first-in-class selective Kv7.2/7.3 ion channel opener designed to address hyperexcitability-induced disease progression in ALS. Kv7.2 is a mis-spliced protein found in sporadic ALS patients.

• In June 2024, Woolsey Pharmaceuticals has reported promising results from its Phase IIa study of BRAVYL, showing a significant reduction in neurofilament light chain (NfL) levels and potential clinical benefits for ALS patients. The open-label, single-arm trial, named Rho Kinase Inhibition in Amyotrophic Lateral Sclerosis (REAL), assessed the initial tolerability, safety, and effects of BRAVYL on clinical outcomes and neurodegeneration biomarkers in ALS patients.

• In February 2024, Biogen Inc. (Nasdaq: BIIB) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the marketing authorization of QALSODY® (tofersen) under exceptional circumstances for the treatment of adults with amyotrophic lateral sclerosis (ALS) linked to a mutation in the superoxide dismutase 1 (SOD1) gene. If approved by the European Commission (EC), QALSODY will become the first treatment in the European Union targeting a genetic cause of ALS, also known as motor neuron disease (MND).

Amyotrophic Lateral Sclerosis Overview

Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease, is a progressive neurodegenerative disorder that affects motor neurons in the brain and spinal cord. These neurons are responsible for controlling voluntary muscle movements, and as they deteriorate, muscles weaken and atrophy. ALS leads to symptoms such as muscle weakness, difficulty speaking and swallowing, and eventually respiratory failure. The exact cause is often unknown, though genetic and environmental factors may contribute. There is no cure, but treatments focus on managing symptoms, improving quality of life, and extending survival.

Get a Free Sample PDF Report to know more about Amyotrophic Lateral Sclerosis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/amyotrophic-lateral-sclerosis-als-pipeline-insight

Emerging Amyotrophic Lateral Sclerosis Drugs Under Different Phases of Clinical Development Include:

• AEZS-130: Aeterna Zentaris

• GNK 301: GeNeuro SA

• Prosetin: ProJenX

• QRL 201: QurAlis Corporation

• WVE-004: Wave Life Sciences

• RNS60: Revalesio Corporation

• AIT-101: AI THERAPEUTICS

• Reldesemtiv: CYTOKINETICS

• ION363: Ionis Pharmaceuticals

Amyotrophic Lateral Sclerosis Route of Administration

Amyotrophic Lateral Sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Intra-articular

• Intraocular

• Intrathecal

• Intravenous

• Ophthalmic

• Oral

• Parenteral

• Subcutaneous

• Topical

• Transdermal

Amyotrophic Lateral Sclerosis Molecule Type

Amyotrophic Lateral Sclerosis Products have been categorized under various Molecule types, such as

• Oligonucleotide

• Peptide

• Small molecule

Amyotrophic Lateral Sclerosis Pipeline Therapeutics Assessment

• Amyotrophic Lateral Sclerosis Assessment by Product Type

• Amyotrophic Lateral Sclerosis By Stage and Product Type

• Amyotrophic Lateral Sclerosis Assessment by Route of Administration

• Amyotrophic Lateral Sclerosis By Stage and Route of Administration

• Amyotrophic Lateral Sclerosis Assessment by Molecule Type

• Amyotrophic Lateral Sclerosis by Stage and Molecule Type

DelveInsight’s Amyotrophic Lateral Sclerosis Report covers around 80+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Amyotrophic Lateral Sclerosis product details are provided in the report. Download the Amyotrophic Lateral Sclerosis pipeline report to learn more about the emerging Amyotrophic Lateral Sclerosis therapies

Some of the key companies in the Amyotrophic Lateral Sclerosis Therapeutics Market include:

Key companies developing therapies for Amyotrophic Lateral Sclerosis are – Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, Alector, GSK, NeuroSense Therapeutics, Biogen, Ionis Pharmaceuticals, Brainstorm Cell Therapeutics, Cytokinetics, Astellas Pharma, Apellis Pharmaceuticals, Clene Nanomedicine Biosciences, AL-S Pharma, MediciNova, Seelos Theraputics, Prilenia Therapeutics, AB Science, Eledon Pharmaceuticals, Revalesio Corporation, Biohaven Pharmaceuticals, UCB Pharma, Ra Pharmaceuticals, AI Therapeutics, and others.

Amyotrophic Lateral Sclerosis Pipeline Analysis:

The Amyotrophic Lateral Sclerosis pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Amyotrophic Lateral Sclerosis with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Amyotrophic Lateral Sclerosis Treatment.

• Amyotrophic Lateral Sclerosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Amyotrophic Lateral Sclerosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Amyotrophic Lateral Sclerosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Amyotrophic Lateral Sclerosis drugs and therapies

Amyotrophic Lateral Sclerosis Pipeline Market Drivers

• Need for disease-specific treatment options, rising geriatric population, increasing research and developmental activities are some of the important factors that are fueling the Amyotrophic Lateral Sclerosis Market.

Amyotrophic Lateral Sclerosis Pipeline Market Barriers

• However, No standard cure for ALS, unknown cause of the disease and other factors are creating obstacles in the Amyotrophic Lateral Sclerosis Market growth.

Scope of Amyotrophic Lateral Sclerosis Pipeline Drug Insight

• Coverage: Global

• Key Amyotrophic Lateral Sclerosis Companies: Aeterna Zentaris, GeNeuro SA, ProJenX, QurAlis Corporation, Wave Life Sciences, Revalesio Corporation, AI THERAPEUTICS, CYTOKINETICS, Ionis Pharmaceuticals, and others

• Key Amyotrophic Lateral Sclerosis Therapies: AEZS-130, GNK 301, Prosetin, QRL 201, WVE-004, RNS60, AIT-101, Reldesemtiv, ION363, and others

• Amyotrophic Lateral Sclerosis Therapeutic Assessment: Amyotrophic Lateral Sclerosis current marketed and Amyotrophic Lateral Sclerosis emerging therapies

• Amyotrophic Lateral Sclerosis Market Dynamics: Amyotrophic Lateral Sclerosis market drivers and Amyotrophic Lateral Sclerosis market barriers

Request for Sample PDF Report for Amyotrophic Lateral Sclerosis Pipeline Assessment and clinical trials

Table of Contents

1. Amyotrophic Lateral Sclerosis Report Introduction

2. Amyotrophic Lateral Sclerosis Executive Summary

3. Amyotrophic Lateral Sclerosis Overview

4. Amyotrophic Lateral Sclerosis- Analytical Perspective In-depth Commercial Assessment

5. Amyotrophic Lateral Sclerosis Pipeline Therapeutics

6. Amyotrophic Lateral Sclerosis Late Stage Products (Phase II/III)

7. Amyotrophic Lateral Sclerosis Mid Stage Products (Phase II)

8. Amyotrophic Lateral Sclerosis Early Stage Products (Phase I)

9. Amyotrophic Lateral Sclerosis Preclinical Stage Products

10. Amyotrophic Lateral Sclerosis Therapeutics Assessment

11. Amyotrophic Lateral Sclerosis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Amyotrophic Lateral Sclerosis Key Companies

14. Amyotrophic Lateral Sclerosis Key Products

15. Amyotrophic Lateral Sclerosis Unmet Needs

16 . Amyotrophic Lateral Sclerosis Market Drivers and Barriers

17. Amyotrophic Lateral Sclerosis Future Perspectives and Conclusion

18. Amyotrophic Lateral Sclerosis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Amyotrophic Lateral Sclerosis Pipeline 2025: MOA and ROA Insights, Clinical Trials, and Key Companies Involved by DelveInsight | Biogen, GSK, Helixmith, Sanofi, Denali Therapeutics, Ionis Pharma

The Acute Kidney Injury Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Acute Kidney Injury Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Acute Kidney Injury Market.

Some of the key takeaways from the Acute Kidney Injury Pipeline Report:

• Companies across the globe are diligently working toward developing novel Acute Kidney Injury treatment therapies with a considerable amount of success over the years.

• Acute Kidney Injury companies working in the treatment market are Revelation Biosciences, RegeneRx Biopharmaceuticals, MISSION Therapeutics, Unicycive Therapeutics, Sentien Biotechnologies, Metro International Biotech, Guard Therapeutics AB, Novartis, Angion Biomedica/Vifor, AM Pharma, Astellas Pharma, Pharming Technologies, RegeneRx Biopharmaceuticals, and others, are developing therapies for the Acute Kidney Injury treatment

• Emerging Acute Kidney Injury therapies in the different phases of clinical trials are- REVTx-300, RGN-352, MTX652, UNI-494, SBI-101, MIB-626, RMC-035, TIN816, ANG-3777, Ilofotase alfa, ASP1128, Ruconest (Conestat alfa), Timbetasin, and others are expected to have a significant impact on the Acute Kidney Injury market in the coming years.

• In January 2025, SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company focused on innovative treatments to mitigate the impact of hyperinflammation on vital organs, has announced that Mayo Clinic has received clearance to enroll participants in its NEUTRALIZE-AKI pivotal trial, bringing the total number of active trial sites to 15.

• In October 2024, Unicycive Therapeutics reported encouraging outcomes from its Phase I clinical trial of UNI-494, a patented pro-drug of nicorandil currently being developed for acute kidney injury (AKI). The study demonstrated that UNI-494 was safe and well-tolerated across both single and multiple ascending dose groups. Additionally, the drug exhibited rapid absorption and metabolism, with plasma concentrations rising proportionally with higher doses.

• In January 2024, Renibus Therapeutics released findings from a Phase II Study investigating RBT-1 as a preoperative treatment to decrease complications after cardiothoracic surgery.

Acute Kidney Injury Overview

Acute Kidney Injury (AKI), formerly known as acute renal failure, is a sudden and rapid decline in kidney function. This condition is characterized by a sudden and significant decrease in the kidneys’ ability to filter and eliminate waste products and excess fluids from the blood. Acute Kidney Injury can occur over a few hours or days, and it is often reversible with appropriate and timely treatment.

Get a Free Sample PDF Report to know more about Acute Kidney Injury Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/acute-kidney-injury-aki-pipeline-insight

Emerging Acute Kidney Injury Drugs Under Different Phases of Clinical Development Include:

• REVTx-300: Revelation Biosciences

• RGN-352: RegeneRx Biopharmaceuticals

• MTX652: MISSION Therapeutics

• UNI-494: Unicycive Therapeutics

• SBI-101: Sentien Biotechnologies

• MIB-626: Metro International Biotech

• RMC-035: Guard Therapeutics AB

• TIN816: Novartis Pharmaceuticals

• ANG-3777: Angion Biomedica/Vifor

• Ilofotase alfa: AM Pharma

• ASP1128: Astellas Pharma

• Ruconest (Conestat alfa): Pharming Technologies

• RMC-035: Guard Therapeutics

• SBI-101: Sentien Biotechnologies

• Timbetasin: RegeneRx Biopharmaceuticals

Acute Kidney Injury Route of Administration

Acute Kidney Injury pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Intravenous

• Subcutaneous

• Parenteral

• Topical

Acute Kidney Injury Molecule Type

Acute Kidney Injury Products have been categorized under various Molecule types, such as

• Recombinant fusion proteins

• Small molecule

• Monoclonal antibody

• Peptide

• Polymer

• Gene therapy

Acute Kidney Injury Pipeline Therapeutics Assessment

• Acute Kidney Injury Assessment by Product Type

• Acute Kidney Injury By Stage and Product Type

• Acute Kidney Injury Assessment by Route of Administration

• Acute Kidney Injury By Stage and Route of Administration

• Acute Kidney Injury Assessment by Molecule Type

• Acute Kidney Injury by Stage and Molecule Type

DelveInsight’s Acute Kidney Injury Report covers around 30+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Acute Kidney Injury product details are provided in the report. Download the Acute Kidney Injury pipeline report to learn more about the emerging Acute Kidney Injury therapies

Some of the key companies in the Acute Kidney Injury Therapeutics Market include:

Key companies developing therapies for Acute Kidney Injury are – Atox Bio, AM Pharma Holding, Quark-Pharmaceuticals, LG Chem, Pharming Group, Angion Biomedica, Elysium Health, Sentien Biotechnologies, Pharmazz, Arch Biopartners, Guard Therapeutics, RegeneRx Biopharmaceuticals, Cerenis Therapeutics Alloksys, Vifor Pharma, Exponential Biotherapies, Astellas Pharma, Amniotics, Mission Therapeutics, Bessor pharma, Kantum Pharma, Nephraegis Therapeutics, Vasomune, Unicycive, ABIONYX and others.

Acute Kidney Injury Pipeline Analysis:

The Acute Kidney Injury pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Acute Kidney Injury with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Kidney Injury Treatment.

• Acute Kidney Injury key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Acute Kidney Injury Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Kidney Injury market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Acute Kidney Injury drugs and therapies

Acute Kidney Injury Pipeline Market Drivers

• Rising incidence of Acute Kidney injuries, the rising geriatric population are some of the important factors that are fueling the Acute Kidney Injury Market.

Acute Kidney Injury Pipeline Market Barriers

• However, side-effects associated with the treatment, lack of awareness and other factors are creating obstacles in the Acute Kidney Injury Market growth.

Scope of Acute Kidney Injury Pipeline Drug Insight

• Coverage: Global

• Key Acute Kidney Injury Companies: Revelation Biosciences, RegeneRx Biopharmaceuticals, MISSION Therapeutics, Unicycive Therapeutics, Sentien Biotechnologies, Metro International Biotech, Guard Therapeutics AB, Novartis, Angion Biomedica/Vifor, AM Pharma, Astellas Pharma, Pharming Technologies, RegeneRx Biopharmaceuticals, and others

• Key Acute Kidney Injury Therapies: REVTx-300, RGN-352, MTX652, UNI-494, SBI-101, MIB-626, RMC-035, TIN816, ANG-3777, Ilofotase alfa, ASP1128, Ruconest (Conestat alfa), Timbetasin, and others

• Acute Kidney Injury Therapeutic Assessment: Acute Kidney Injury current marketed and Acute Kidney Injury emerging therapies

• Acute Kidney Injury Market Dynamics: Acute Kidney Injury market drivers and Acute Kidney Injury market barriers

Request for Sample PDF Report for Acute Kidney Injury Pipeline Assessment and clinical trials

Table of Contents

1. Acute Kidney Injury Report Introduction

2. Acute Kidney Injury Executive Summary

3. Acute Kidney Injury Overview

4. Acute Kidney Injury- Analytical Perspective In-depth Commercial Assessment

5. Acute Kidney Injury Pipeline Therapeutics

6. Acute Kidney Injury Late Stage Products (Phase II/III)

7. Acute Kidney Injury Mid Stage Products (Phase II)

8. Acute Kidney Injury Early Stage Products (Phase I)

9. Acute Kidney Injury Preclinical Stage Products

10. Acute Kidney Injury Therapeutics Assessment

11. Acute Kidney Injury Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Acute Kidney Injury Key Companies

14. Acute Kidney Injury Key Products

15. Acute Kidney Injury Unmet Needs

16 . Acute Kidney Injury Market Drivers and Barriers

17. Acute Kidney Injury Future Perspectives and Conclusion

18. Acute Kidney Injury Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Acute Kidney Injury Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Astellas Pharma, Amniotics, Guard Therapeutics, RegeneRx Biopharma

DelveInsight’s “Night Vision Disturbances Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Night Vision Disturbances, historical and forecasted epidemiology as well as the Night Vision Disturbances market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Night Vision Disturbances, offering comprehensive insights into the Night Vision Disturbances revenue trends, prevalence, and treatment landscape. The report delves into key Night Vision Disturbances statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Night Vision Disturbances therapies. Additionally, we cover the landscape of Night Vision Disturbances clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Night Vision Disturbances treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Night Vision Disturbances space.

To Know in detail about the Night Vision Disturbances market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Night Vision Disturbances Market Forecast

Some of the key facts of the Night Vision Disturbances Market Report:

• The Night Vision Disturbances market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In February 2025, Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotech company focused on developing gene therapies for inherited retinal diseases (IRDs) and other eye disorders, has announced the completion of patient enrollment in the VEGA-3 Phase 3 clinical trial of Phentolamine Ophthalmic Solution 0.75% for treating presbyopia. Additionally, the company reported that enrollment in the LYNX-2 pivotal Phase 3 trial—targeting visual loss in low light conditions following keratorefractive surgery—is progressing well, with enrollment expected to be completed in the first half of 2025.

• In September 2024, Johnson & Johnson, a global leader in eye care, announced the expanded U.S. launch of its latest presbyopia-correcting intraocular lens (PC-IOL), TECNIS Odyssey. This innovative IOL delivers an unparalleled continuous range of vision, allowing patients to see clearly from far to near and intermediate distances, significantly reducing the need for glasses. Built on the TECNIS platform, TECNIS Odyssey offers double the contrast in low-light conditions compared to PanOptix. Additionally, patients with TECNIS Odyssey IOL can read 14% smaller print on average than those with PanOptix IOL, and 93% reported no or mild visual disturbances such as halos, glare, or starbursts one month post-surgery.

• In January 2024, Ocuphire Pharma secured US FDA Agreement under an SPA, leading to the initiation of the LYNX-2 Phase III trial in April 2024 to evaluate Phentolamine Ophthalmic Solution for improving night vision post-refractive surgery.

• In 2023, the Night Vision Disturbance (NVD) market, including supportive care, was valued at USD 3,216 million across the 7MM. The market is anticipated to grow with the expected introduction of emerging therapies during the forecast period (2024–2034).

• In 2023, the US held the largest market size for Night Vision Disturbance (NVD) among the 7MM, with an estimated USD 1,754 million. This market is expected to grow at a CAGR of 1.08% through 2034.

• In 2023, Germany had the largest market size for Night Vision Disturbance (NVD) among EU countries, with nearly USD 283 million, while Spain had the smallest market size, at approximately USD 149 million.

• In 2023, the market size for Night Vision Disturbance (NVD) in Japan was estimated to be approximately USD 434 million.

• Key Night Vision Disturbances Companies: Ocuphire Pharma/Viatris, and others

• Key Night Vision Disturbances Therapies: Phentolamine Ophthalmic Solution 0.75% (Nyxol), and others

• The Night Vision Disturbances market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Night Vision Disturbances pipeline products will significantly revolutionize the Night Vision Disturbances market dynamics.

• DelveInsight’s assessment estimated that the total diagnosed prevalent cases of Night Vision Disturbance (NVD) across the 7MM reached nearly 55 million in 2023.

• In 2023, the US accounted for the largest share of total diagnosed prevalent cases of Night Vision Disturbance (NVD), representing 44%, and this number is expected to increase in the future.

• In 2023, Germany reported the highest number of diagnosed prevalent cases of Night Vision Disturbance (NVD) among European countries, with around 6 million cases, followed by France with approximately 4 million cases. Spain had the lowest prevalence, with about 3 million cases.

• In 2023, Japan reported nearly 9 million diagnosed prevalent cases of Night Vision Disturbance (NVD), representing about 16% of the total cases across the 7MM.

Night Vision Disturbances Overview

Night Vision Disturbance refers to difficulties or impairments in seeing clearly in low-light or nighttime conditions. This condition can be caused by various factors, including aging, underlying health issues such as cataracts, retinal diseases, or conditions like vitamin A deficiency. Individuals with NVD often experience reduced visual acuity, glare, halos, or difficulty adjusting to darkness, which can impact daily activities such as driving at night or navigating low-light environments. Treatment and management typically focus on addressing the underlying causes of the disturbance.

Get a Free sample for the Night Vision Disturbances Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/night-vision-disturbances-market

Night Vision Disturbances Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Night Vision Disturbances Epidemiology Segmentation:

The Night Vision Disturbances market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Night Vision Disturbances

• Prevalent Cases of Night Vision Disturbances by severity

• Gender-specific Prevalence of Night Vision Disturbances

• Diagnosed Cases of Episodic and Chronic Night Vision Disturbances

Download the report to understand which factors are driving Night Vision Disturbances epidemiology trends @ Night Vision Disturbances Epidemiology Forecast

Night Vision Disturbances Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Night Vision Disturbances market or expected to get launched during the study period. The analysis covers Night Vision Disturbances market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Night Vision Disturbances Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Night Vision Disturbances Therapies and Key Companies

• Phentolamine Ophthalmic Solution 0.75% (Nyxol): Ocuphire Pharma/Viatris

Discover more about therapies set to grab major Night Vision Disturbances market share @ Night Vision Disturbances Treatment Landscape

Night Vision Disturbances Market Drivers

• Aging Population

• Growing Awareness

• Technological Advancements

• Increased Research & Development

• Rising Prevalence of Retinal Diseases

• Emerging Therapies

Night Vision Disturbances Market Barriers

• High Treatment Costs

• Limited Awareness in Rural Areas

• Availability of Standardized Treatment

• Slow Adoption of New Therapies

• Complex Regulatory Approvals

Scope of the Night Vision Disturbances Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Night Vision Disturbances Companies: Phentolamine Ophthalmic Solution 0.75% (Nyxol), and others

• Key Night Vision Disturbances Therapies: Ocuphire Pharma/Viatris, and others

• Night Vision Disturbances Therapeutic Assessment: Night Vision Disturbances current marketed and Night Vision Disturbances emerging therapies

• Night Vision Disturbances Market Dynamics: Night Vision Disturbances market drivers and Night Vision Disturbances market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Night Vision Disturbances Unmet Needs, KOL’s views, Analyst’s views, Night Vision Disturbances Market Access and Reimbursement

To know more about Night Vision Disturbances companies working in the treatment market, visit @ Night Vision Disturbances Clinical Trials and Therapeutic Assessment

Table of Contents

1. Night Vision Disturbances Market Report Introduction

2. Executive Summary for Night Vision Disturbances

3. SWOT analysis of Night Vision Disturbances

4. Night Vision Disturbances Patient Share (%) Overview at a Glance

5. Night Vision Disturbances Market Overview at a Glance

6. Night Vision Disturbances Disease Background and Overview

7. Night Vision Disturbances Epidemiology and Patient Population

8. Country-Specific Patient Population of Night Vision Disturbances

9. Night Vision Disturbances Current Treatment and Medical Practices

10. Night Vision Disturbances Unmet Needs

11. Night Vision Disturbances Emerging Therapies

12. Night Vision Disturbances Market Outlook

13. Country-Wise Night Vision Disturbances Market Analysis (2020–2034)

14. Night Vision Disturbances Market Access and Reimbursement of Therapies

15. Night Vision Disturbances Market Drivers

16. Night Vision Disturbances Market Barriers

17. Night Vision Disturbances Appendix

18. Night Vision Disturbances Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Night Vision Disturbances Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Ocuphire Pharma, Viatris

DelveInsight’s “Systemic Sclerosis-associated Interstitial Lung Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Systemic Sclerosis-associated Interstitial Lung Disease, historical and forecasted epidemiology as well as the Systemic Sclerosis-associated Interstitial Lung Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Systemic Sclerosis-associated Interstitial Lung Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; SSc-ILD Market Forecast

Some of the key facts of the Systemic Sclerosis-associated Interstitial Lung Disease Market Report:

• The Systemic Sclerosis-associated Interstitial Lung Disease market size was valued approximately USD 750 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In February 2025, Boehringer Ingelheim’s lung disease drug, nerandomilast, demonstrated success in a Phase III trial, positioning the company to seek approval for its use in a second condition. Topline results from the Phase III FIBRONEER-ILD trial (NCT05321082) showed that nerandomilast improved lung function in patients with progressive fibrosing interstitial lung diseases (PF-ILDs), excluding idiopathic pulmonary fibrosis (IPF). Previously, Boehringer conducted a separate IPF trial, which supported its new drug application (NDA) submission last year. The company’s Ofev remains the standard of care (SOC) and is one of only two approved treatments for IPF. It is also approved for systemic sclerosis-associated interstitial lung disease (SSc-ILD) and other chronic interstitial lung diseases.

• In November 2024, Zura Bio Limited (Nasdaq: ZURA), a clinical-stage immunology company focused on developing innovative dual-pathway antibodies for autoimmune and inflammatory diseases, has submitted a protocol to its open Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA). The submission is for a Phase 2 study evaluating tibulizumab, a humanized tetravalent bispecific dual antagonist antibody that targets both IL-17A and BAFF, for the treatment of systemic sclerosis (SSc) in adults.

• In June 2024, MDI Therapeutics has initiated dosing in a Phase I trial to advance the development of a potential treatment for systemic sclerosis (SSc) and interstitial lung disease (ILD). The study’s primary objective is to evaluate the safety and tolerability of MDI-2517, an investigational inhibitor targeting plasminogen activator inhibitor 1 (PAI-1).

• The existing pipeline for Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) includes prospective drugs with the potential to impact market dynamics. PRA023, Belimumab (GSK1550188), Vixarelimab (KPL-716), and several others are among the prominently featured drugs for this indication.

• The collective diagnosed prevalent population of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) in the 7MM reached approximately 53,178 in 2022. There is an anticipated substantial increase in these cases at a notable Compound Annual Growth Rate (CAGR) over the study period from 2020 to 2034.

• Within the European countries, the United Kingdom exhibited the highest number of diagnosed prevalent cases of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD), totaling around 4,269 cases in 2022. Italy and France followed closely in the same year. In contrast, Germany had the lowest diagnosed prevalent population in that specific year.

• According to the analysis, it has been noted that the age group with the highest number of diagnosed patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) is 65 and above, while the lowest incidence is observed in the 0-18 age group.

• Key Systemic Sclerosis-associated Interstitial Lung Disease Companies: Prometheus Biosciences, Inc., MERCK, GlaxoSmithKline, Genentech, Inc., Acceleron, Boehringer Ingelheim, Actelion, Hôpital Claude-Huriez, Changchun GeneScience Pharmaceutical, and others

• Key Systemic Sclerosis-associated Interstitial Lung Disease Therapies: PRA023, Belimumab, Vixarelimab, MK-2225 (ACE-1334), Nintedanib, bosentan, Belimumab, Cyclophosphamide, GenSci048, and others

• The Systemic Sclerosis-associated Interstitial Lung Disease epidemiology based on gender analyzed that females are more likely to get affected by SSc-ILD in comparison to male

• The Systemic Sclerosis-associated Interstitial Lung Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Systemic Sclerosis-associated Interstitial Lung Disease pipeline products will significantly revolutionize the Systemic Sclerosis-associated Interstitial Lung Disease market dynamics.

Systemic Sclerosis-associated Interstitial Lung Disease Overview

Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) is a complication associated with systemic sclerosis (SSc), also known as scleroderma. Systemic sclerosis is a chronic autoimmune connective tissue disorder characterized by abnormal immune system activity, vascular problems, and excessive collagen deposition in the skin and other organs.

Get a Free sample for the Systemic Sclerosis-associated Interstitial Lung Disease Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/systemic-sclerosis-associated-interstitial-lung-disease-ssc-ild-market

Systemic Sclerosis-associated Interstitial Lung Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Systemic Sclerosis-associated Interstitial Lung Disease Epidemiology Segmentation:

The Systemic Sclerosis-associated Interstitial Lung Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Systemic Sclerosis-associated Interstitial Lung Disease

• Prevalent Cases of Systemic Sclerosis-associated Interstitial Lung Disease by severity

• Gender-specific Prevalence of Systemic Sclerosis-associated Interstitial Lung Disease

• Diagnosed Cases of Episodic and Chronic Systemic Sclerosis-associated Interstitial Lung Disease

Download the report to understand which factors are driving Systemic Sclerosis-associated Interstitial Lung Disease epidemiology trends @ SSc-ILD Epidemiology Forecast

Systemic Sclerosis-associated Interstitial Lung Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Systemic Sclerosis-associated Interstitial Lung Disease market or expected to get launched during the study period. The analysis covers Systemic Sclerosis-associated Interstitial Lung Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Systemic Sclerosis-associated Interstitial Lung Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Systemic Sclerosis-associated Interstitial Lung Disease Therapies and Key Companies

• PRA023: Prometheus Biosciences, Inc./ MERCK

• Belimumab: GlaxoSmithKline

• Vixarelimab: Genentech, Inc.

• MK-2225 (ACE-1334): Acceleron/ MERCK

• Nintedanib: Boehringer Ingelheim

• bosentan: Actelion

• Belimumab: GlaxoSmithKline

• Cyclophosphamide: Hôpital Claude-Huriez

• GenSci048: Changchun GeneScience Pharmaceutical

Discover more about therapies set to grab major Systemic Sclerosis-associated Interstitial Lung Disease market share @ Systemic Sclerosis-associated Interstitial Lung Disease Treatment Landscape

Systemic Sclerosis-associated Interstitial Lung Disease Market Strengths

• The shortfall of therapeutic candidates in the emerging pipeline as well as in the market can give an advantage to emerging therapy to gain huge market share with lesser competition.

Systemic Sclerosis-associated Interstitial Lung Disease Market Opportunities

• The scarcity of approved treatment options offers a great opportunity for the investment and development of novel therapies.

Scope of the Systemic Sclerosis-associated Interstitial Lung Disease Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Systemic Sclerosis-associated Interstitial Lung Disease Companies: Prometheus Biosciences, Inc., MERCK, GlaxoSmithKline, Genentech, Inc., Acceleron, Boehringer Ingelheim, Actelion, Hôpital Claude-Huriez, Changchun GeneScience Pharmaceutical, and others

• Key Systemic Sclerosis-associated Interstitial Lung Disease Therapies: PRA023, Belimumab, Vixarelimab, MK-2225 (ACE-1334), Nintedanib, bosentan, Belimumab, Cyclophosphamide, GenSci048, and others

• Systemic Sclerosis-associated Interstitial Lung Disease Therapeutic Assessment: Systemic Sclerosis-associated Interstitial Lung Disease current marketed and Systemic Sclerosis-associated Interstitial Lung Disease emerging therapies

• Systemic Sclerosis-associated Interstitial Lung Disease Market Dynamics: Systemic Sclerosis-associated Interstitial Lung Disease market drivers and Systemic Sclerosis-associated Interstitial Lung Disease market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Systemic Sclerosis-associated Interstitial Lung Disease Unmet Needs, KOL’s views, Analyst’s views, Systemic Sclerosis-associated Interstitial Lung Disease Market Access and Reimbursement

To know more about Systemic Sclerosis-associated Interstitial Lung Disease companies working in the treatment market, visit @ SSc-ILD Clinical Trials and Therapeutic Assessment

Table of Contents

1. Systemic Sclerosis-associated Interstitial Lung Disease Market Report Introduction

2. Executive Summary for Systemic Sclerosis-associated Interstitial Lung Disease

3. SWOT analysis of Systemic Sclerosis-associated Interstitial Lung Disease

4. Systemic Sclerosis-associated Interstitial Lung Disease Patient Share (%) Overview at a Glance

5. Systemic Sclerosis-associated Interstitial Lung Disease Market Overview at a Glance

6. Systemic Sclerosis-associated Interstitial Lung Disease Disease Background and Overview

7. Systemic Sclerosis-associated Interstitial Lung Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Systemic Sclerosis-associated Interstitial Lung Disease

9. Systemic Sclerosis-associated Interstitial Lung Disease Current Treatment and Medical Practices

10. Systemic Sclerosis-associated Interstitial Lung Disease Unmet Needs

11. Systemic Sclerosis-associated Interstitial Lung Disease Emerging Therapies

12. Systemic Sclerosis-associated Interstitial Lung Disease Market Outlook

13. Country-Wise Systemic Sclerosis-associated Interstitial Lung Disease Market Analysis (2020–2034)

14. Systemic Sclerosis-associated Interstitial Lung Disease Market Access and Reimbursement of Therapies

15. Systemic Sclerosis-associated Interstitial Lung Disease Market Drivers

16. Systemic Sclerosis-associated Interstitial Lung Disease Market Barriers

17. Systemic Sclerosis-associated Interstitial Lung Disease Appendix

18. Systemic Sclerosis-associated Interstitial Lung Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: SSc-ILD Market on Track for Major Expansion by 2034, According to DelveInsight | MERCK, GlaxoSmithKline, Genentech, Acceleron, Prometheus Biosciences, Boehringer Ingelheim, Actelion,

DelveInsight’s “Limbal Stem Cells Deficiency Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Limbal Stem Cells Deficiency, historical and forecasted epidemiology as well as the Limbal Stem Cells Deficiency market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Limbal Stem Cells Deficiency market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Limbal Stem Cells Deficiency Market Forecast

Some of the key facts of the Limbal Stem Cells Deficiency Market Report:

• The Limbal Stem Cells Deficiency market size was valued approximately USD 2,690 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In 2023, the United States held the largest share of the Limbal Stem Cell Deficiency (LSCD) market among the 7MM, with an estimated market size of around USD 1,500 million, while Spain had the smallest share at approximately USD 127 million. This pattern is anticipated to persist throughout the forecast period.In 2023, within the EU4 countries, Germany, France, and Italy recorded the highest Limbal Stem Cell Deficiency market sizes at USD 220 million, USD 180 million, and USD 160 million, respectively, whereas Spain had the smallest market size at USD 120 million.

• Japan reported a market size of USD 290 million in 2023; however, these dynamics are anticipated to change during the forecast period.

• At present, the only medications approved for treating LSCD patients are HOLOCLAR (autologous human corneal epithelial cells that contain stem cells) and OCURAL (human autologous oral mucosa-derived epithelial cell sheet).

• In 2023, there were an estimated 241,000 diagnosed prevalent cases of LSCD across the 7MM, with approximately 103,000 of those cases originating from the US. These figures are expected to rise during the forecast period.

• The type-specific cases of LSCD were categorized into unilateral and bilateral classifications. In 2023, Japan reported 24,000 cases of unilateral LSCD and 13,000 cases of bilateral LSCD.

• The diagnosed prevalent cases of LSCD were further categorized by gender. In the US in 2023, there were 66,000 cases among males and 37,000 cases among females. These figures are projected to rise by 2034.

• Key Limbal Stem Cells Deficiency Companies: Kala Pharmaceuticals, CLIPS BnC Co., Ltd, RHEACELL GmbH, Holostem Terapie Avanzate, and others

• Key Limbal Stem Cells Deficiency Therapies: KPI-012, LSCD101, LSC2, Implant of Holoclar, and others

• The Limbal Stem Cells Deficiency epidemiology based on gender analyzed that out of the total diagnosed prevalent cases of LSCD in 7MM, about 66% were male

• The Limbal Stem Cells Deficiency market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Limbal Stem Cells Deficiency pipeline products will significantly revolutionize the Limbal Stem Cells Deficiency market dynamics.

Limbal Stem Cells Deficiency Overview

Limbal Stem Cell Deficiency is a condition characterized by the loss or dysfunction of limbal stem cells, which are responsible for regenerating the corneal epithelium, the outermost layer of the cornea. The cornea is the transparent, dome-shaped surface covering the front of the eye, and its epithelium plays a crucial role in maintaining its clarity and integrity.

Get a Free sample for the Limbal Stem Cells Deficiency Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/limbal-stem-cells-deficiency-lsd-market

Limbal Stem Cells Deficiency Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Limbal Stem Cells Deficiency Epidemiology Segmentation:

The Limbal Stem Cells Deficiency market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Limbal Stem Cells Deficiency

• Prevalent Cases of Limbal Stem Cells Deficiency by severity

• Gender-specific Prevalence of Limbal Stem Cells Deficiency

• Diagnosed Cases of Episodic and Chronic Limbal Stem Cells Deficiency

Download the report to understand which factors are driving Limbal Stem Cells Deficiency epidemiology trends @ Limbal Stem Cells Deficiency Epidemiology Forecast

Limbal Stem Cells Deficiency Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Limbal Stem Cells Deficiency market or expected to get launched during the study period. The analysis covers Limbal Stem Cells Deficiency market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Limbal Stem Cells Deficiency Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Limbal Stem Cells Deficiency Therapies and Key Companies

• KPI-012: Kala Pharmaceuticals

• LSCD101: CLIPS BnC Co., Ltd

• LSC2: RHEACELL GmbH

• Implant of Holoclar: Holostem Terapie Avanzate

Discover more about therapies set to grab major Limbal Stem Cells Deficiency market share @ Limbal Stem Cells Deficiency Treatment Landscape

Limbal Stem Cells Deficiency Market Strengths

• Growth in research and developmental activities about this indication can give good returns in the future.

• Early referral to specialized LSCD treatment centers, especially for moderate/severe cases

Limbal Stem Cells Deficiency Market Opportunities

• A multidisciplinary approach is necessary for the preparation of stem cell transplantation

• Consensus guidelines for the diagnosis and management of LSCD established by the Cornea Society’s Limbal Stem Cell Working Group will help improve and bring consistency to the diagnosis and management of the disease.

Scope of the Limbal Stem Cells Deficiency Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Limbal Stem Cells Deficiency Companies: Kala Pharmaceuticals, CLIPS BnC Co., Ltd, RHEACELL GmbH, Holostem Terapie Avanzate, and others

• Key Limbal Stem Cells Deficiency Therapies: KPI-012, LSCD101, LSC2, Implant of Holoclar, and others

• Limbal Stem Cells Deficiency Therapeutic Assessment: Limbal Stem Cells Deficiency current marketed and Limbal Stem Cells Deficiency emerging therapies

• Limbal Stem Cells Deficiency Market Dynamics: Limbal Stem Cells Deficiency market drivers and Limbal Stem Cells Deficiency market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Limbal Stem Cells Deficiency Unmet Needs, KOL’s views, Analyst’s views, Limbal Stem Cells Deficiency Market Access and Reimbursement

To know more about Limbal Stem Cells Deficiency companies working in the treatment market, visit @ Limbal Stem Cells Deficiency Clinical Trials and Therapeutic Assessment

Table of Contents

1. Limbal Stem Cells Deficiency Market Report Introduction

2. Executive Summary for Limbal Stem Cells Deficiency

3. SWOT analysis of Limbal Stem Cells Deficiency

4. Limbal Stem Cells Deficiency Patient Share (%) Overview at a Glance

5. Limbal Stem Cells Deficiency Market Overview at a Glance

6. Limbal Stem Cells Deficiency Disease Background and Overview

7. Limbal Stem Cells Deficiency Epidemiology and Patient Population

8. Country-Specific Patient Population of Limbal Stem Cells Deficiency

9. Limbal Stem Cells Deficiency Current Treatment and Medical Practices

10. Limbal Stem Cells Deficiency Unmet Needs

11. Limbal Stem Cells Deficiency Emerging Therapies

12. Limbal Stem Cells Deficiency Market Outlook

13. Country-Wise Limbal Stem Cells Deficiency Market Analysis (2020–2034)

14. Limbal Stem Cells Deficiency Market Access and Reimbursement of Therapies

15. Limbal Stem Cells Deficiency Market Drivers

16. Limbal Stem Cells Deficiency Market Barriers

17. Limbal Stem Cells Deficiency Appendix

18. Limbal Stem Cells Deficiency Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Limbal Stem Cells Deficiency Market Growth Projections 2024-2034: DelveInsight Analysis | Kala Pharma, CLIPS BnC Co., RHEACELL GmbH, Holostem Terapie Avanzate